papiliximab / Shaperon - LARVOL DELTA

Shaperon presents poster of nanobody bispecific antibody papiliximab at AACR [Google translation] (Hankyung) - "Shaperon announced on the 17th that it held a poster presentation on papiliximab, a nanobody bispecific antibody that simultaneously inhibits adaptive and innate immune checkpoints, at the American Association for Cancer Research (AACR) held in San Diego from the 5th to the 10th...Papiliximab, developed independently by Shaperon, is a double antibody nanobody treatment that dramatically increases the anti-cancer effect on cancers resistant to existing PD-1/PD-L1 antibody treatments and at the same time solves the side effect issues of CD47 antibodies. Papiliximab does not cause red blood cell hemolysis even at high concentrations and does not show the side effects of existing CD47 antibodies....'The selection and presentation of the poster for Papiliximab was recognized for its excellent anti-cancer effect and its excellent safety compared to existing competitive products.'"

Preclinical • Oncology

Papiliximab, a bispecific nanobody targeting CD47 and PDL1 retards tumor growth without hemolysis (AACR 2024) - "These observations suggest that Papiliximab might be able to improve clinical remission more effectively than the combination of monotherapies without the risk of anemia associated with anti-CD47 MoAbs. We are now working to elucidate the mechanisms behind Papiliximab's superior efficacy and safety compared to the combination of monotherapies."

IO biomarker • Breast Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • IFNG • SIRPA